Brind.
  1. An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi.

Brincidofovir is being evaluated as an antiviral treatment for Mpox infections in the DRC, following a WHO PHEIC declaration.

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Brincidofovir is being evaluated as an antiviral treatment for Mpox infections in the DRC, following a WHO PHEIC declaration.

Who's involved

What this event is mainly about
Democratic Republic of the Congo

Keep exploring

Part of

An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireNew Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox Ongoing mpox outbreak continues to be a global health threat and is drivin